Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

5.6%

10 terminated/withdrawn out of 177 trials

Success Rate

85.9%

-0.6% vs industry average

Late-Stage Pipeline

16%

28 trials in Phase 3/4

Results Transparency

21%

13 of 61 completed trials have results

Key Signals

34 recruiting13 with results8 terminated

Enrollment Performance

Analytics

Phase 2

35(30.2%)

Phase 3

28(24.1%)

Phase 1

28(24.1%)

N/A

25(21.6%)

116Total

Phase 2(35)

Phase 3(28)

Phase 1(28)

N/A(25)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (177)

Showing 20 of 177 trials

NCT05782361Phase 1Active Not Recruiting

POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC

Role: lead

NCT02587455Phase 1Completed

Pembrolizumab and Palliative Radiotherapy in Lung

Role: collaborator

NCT05581121Phase 3Recruiting

PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer

Role: collaborator

NCT07002320Phase 1Recruiting

Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer

Role: lead

NCT07529418Not Yet Recruiting

The BALANCE Study: BlAck and Mixed Men's Lived Experience With Prostate cANCEr-Diversity in Prostate Cancer PROMS Study

Role: lead

NCT02819752Phase 1Terminated

PEmbrolizumab Combined With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck

Role: collaborator

NCT06396754Not Yet Recruiting

Deployment and Clinical Evaluation of an AI-powered Digital Oncology Biomarker Tool to guidE Treatment in TNBC

Role: lead

NCT03809377Active Not Recruiting

Transcriptional Responses as an Indicator of Individualised Responses to Radiation Effects (RTGene 2)

Role: lead

NCT07498829Not ApplicableRecruiting

Population Based Germline Testing for Early Detection and Prevention of Cancer

Role: collaborator

NCT03946202Phase 2Recruiting

KORTUC Phase II - Intra-tumoural Radiation Sensitizer in Patients With Locally Advanced/Recurrent Breast Cancer

Role: lead

NCT07372885Phase 1Not Yet Recruiting

GRanulocyte Augmented Cord Blood Transplantation for Poor Risk leukaEmia

Role: collaborator

NCT03875820Phase 1Active Not Recruiting

Phase I Trial of Defactinib and VS-6766.

Role: lead

NCT00578240Active Not Recruiting

Molecular Studies and Clinical Correlations in Human Prostatic Disease

Role: collaborator

NCT04802590Phase 2Active Not Recruiting

Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

Role: collaborator

NCT07432932Recruiting

Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients

Role: collaborator

NCT04065269Phase 2Active Not Recruiting

ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss

Role: lead

NCT04151134Active Not Recruiting

Evaluation of Tongue Base MucOsectomy & Step sErial Sectioning

Role: collaborator

NCT05082259Phase 1Recruiting

ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab

Role: lead

NCT07391215Phase 1Recruiting

5G-PEARL: Paxalisib in Malignant Brain Tumours

Role: lead

NCT02955082Phase 2Active Not Recruiting

The BARCODE 2 Study - The Use of Genetic Profiling to Guide Prostate Cancer Treatment

Role: lead